May 29th 2025
Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.
CVS expands its Project Health program
November 7th 2014Over the next four months, CVS’ Project Health wellness programs will provide more than $14 million in free health services to communities throughout the United States with significant numbers of uninsured or underinsured patients, the company recently announced.
Pharmacists front-line defenders against Ebola anxieties
October 22nd 2014As fears of the Ebola virus and other infectious diseases rise, pharmacists will undoubtedly be called upon to provide patients with public health information and referrals to appropriate care, according to the American Pharmacists Association.
NCPA continues push for any willing pharmacy provision for Medicare Part D plans
October 22nd 2014The National Community Pharmacists Association (NCPA) continues to advocate for legislation that would allow community pharmacies to participate in all Medicare Part D drug plan networks, including “preferred” networks.
Win-win: How retail pharmacists can help health plans with CMS Star Ratings measures
October 10th 2014Health plans that have not scored at least three stars for the last three consecutive years will be vulnerable to elimination from the Medicare system. Pharmacists are in an ideal position to help with those scores.
FDA approves tiotropium bromide mist for COPD
September 25th 2014FDA approved tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim Pharmaceuticals) inhalation spray for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and to reduce exacerbations in patients with COPD.
Project IMPACT: Diabetes shows value of pharmacist patient care services
September 23rd 2014Pharmacists delivering patient care services as part of patient-centered, interdisciplinary healthcare teams can make a difference for diabetes patients who are disproportionately affected by the disease and have limited access to quality care, according to the final results of Project IMPACT: Diabetes.
FDA approves once-weekly GLP-1 receptor agonist for type 2 diabetes
September 19th 2014FDA has approved dulaglutide (Trulicity, Eli Lilly) to treat type 2 diabetes mellitus. The drug is a once-weekly subcutaneous injection used to improve glycemic control and is indicated as an adjunct to diet and exercise in the management of type 2 diabetes in adults.